Shire’s once daily ADHD medication Venvanse (know as Vyvanse in the USA and Canada) has been accepted for review by UK regulator, the MHRA. This is the first step for this medication to gain entry into Europe. In fact, this would be the first amphetamine based ADHD medication in Europe. While most European countries have Methylphenidate medications (such as Ritalin and Concerta) and the non-stimulant Atomoxetine (Strattera), they do not have any of the amphetamine based medications which are available in other countries (such as Adderall, Adderall XR, Vyvanse and Dexedrine).
This news was reported on January 6, 2012. It is not clear how long the review will take, and when Venvanse will actually become available in the UK, and other European countries.